New Report Available: Sweden Pharmaceuticals & Healthcare Report Q3 2013
While we expect that the Swedish pharmaceutical market will decline in coming years, under pressure from generic medicines, patent expirations and a general climate of cost containment, we remain optimistic about the country's long-term attractiveness. This view covers both consumption (which is supported by well-developed public financing and healthcare systems) and research and development (R&D) initiatives in the country, with global pharmaceutical major AstraZeneca recently confirming its commitment to local R&D activities.
View full press release